This segment focused on the research, development, and clinical trials of innovative protein therapeutics for various cancers. The primary focus was on bemarituzumab, an antibody targeting FGFR2b, which was in Phase 3 clinical trials for gastric and gastroesophageal junction (GEJ) cancer. Research and development activities included identifying and validating therapeutic targets, designing and engineering protein therapeutics, conducting preclinical studies, and managing clinical trials. The segment utilized technologies such as antibody engineering and protein therapeutics development. The goal was to improve patient outcomes by providing targeted therapies with the potential to improve survival rates and quality of life. Market positioning involved strategic partnerships with companies like Zai Lab for commercialization in specific regions. The acquisition by Amgen provided the opportunity to integrate and expand the oncology pipeline.

This segment concentrated on developing immunomodulatory therapies to harness the power of the immune system to fight cancer. This included the development of FPA150, a CD8 T cell checkpoint inhibitor antibody targeting B7-H4, and FPT155, a soluble CD80 fusion protein designed to enhance T cell co-stimulation. Research and development activities involved identifying and validating immune checkpoints, designing and engineering antibodies and fusion proteins, and conducting preclinical and clinical trials. The segment utilized technologies such as antibody engineering and immunotherapeutic approaches. The therapeutic areas covered included various cancers, with the aim of improving patient outcomes through enhanced immune responses. Market positioning involved collaborations with companies like Bristol-Myers Squibb to explore novel immuno-oncology therapies. The acquisition by Amgen provided the opportunity to integrate and expand the immuno-oncology pipeline.